Pharma BD Deal Intelligence

Servier Pharmaceuticals LLC / Agios Pharmaceuticals Inc.

2020 · Asset Purchase · $2.0B · Complete

Announcement Sentiment

Strongly positive

Outcome Score

Worked — the deal delivered on its rationale.

Servier acquired Agios Pharmaceuticals' entire oncology business for up to $2 billion ($1.8 billion upfront plus $200 million in regulatory milestones) plus royalties, gaining Tibsovo (ivosidenib), vorasidenib (brain-penetrant dual IDH1/IDH2 inhibitor), and a portfolio of IDH-mutant oncology assets.

Key facts

Announced Dec 21, 2020
Closed Apr 01, 2021
Deal value $2.0B
Deal type Asset Purchase
Therapeutic area Oncology
Indications IDH1-Mutant Acute Myeloid Leukemia, IDH-Mutant Low-Grade Glioma, IDH1-Mutant Cholangiocarcinoma, Myelodysplastic Syndrome
Key assets ivosidenib (Tibsovo), vorasidenib, enasidenib (IDHIFA), AG-270, IDH oncology research portfolio
Mechanism IDH1 inhibitor, Dual IDH1/IDH2 inhibitor (brain-penetrant), IDH2 inhibitor, MAT2A inhibitor

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals